Bioventix (BVXP)

 
Due to recent changes by the London Stock Exchange relating to MiFID II, some AIM stocks are trading off‑book and therefore not showing recent prices, price changes or trades. We are working with the LSE to improve this situation.

BVXP Share PerformanceMore

52 week high2,950.0 09/10/17
52 week low26.0 15/11/17
52 week change 1,225.0 (89.09%)
4 week volume82,598 29/10/17

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Director Deals - Bioventix Plc (BVXP)

Peter Harrison, Chief Executive Officer, sold 80,000 shares in the company on the 19th October 2017 at a price of 2425.00p. ...

Director Deals - Bioventix Plc (BVXP)

Ian Nicholson, Chairman, sold 5,000 shares in the company on the 19th October 2017 at a price of 2400.75p. The Director no...

Director/PDMR Shareholding

Bioventix plc (?Bioventix? or the ?Company?) Director/PDMR Shareholding Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for application in clinical diagnostics, was notified on 19 October 2017 of the following transactions in its ordinary shares of 5 pence each (?Ordinary Shares?)...

Holding(s) in Company

TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: BIOVENTIX 1b. Please indicate if the issuer is a non-UK issuer (please mark...

Broker Forecast - finnCap issues a broker note on Bioventix Plc

finnCap today reaffirms its corporate investment rating on Bioventix Plc (LON:BVXP) and set its price target at 2600p.

Bioventix pre-tax profits up 37%

Pre-tax profits at Bioventix rose by 37% to 5.7m in the year to the end of June. Revenues rose by 31% to 7.2m and were ahe...

Final Results

Bioventix plc (?Bioventix? or the ?Company?) Preliminary results for the year ended 30 June 2017 Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces its audited results for the year ended 30 June 2017. Highlights: ? Revenue up 31% to ?7.2...

Holding(s) in Company

TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: BIOVENTIX PLC 1b. Please indicate if the issuer is a non-UK issuer (please ...

Fundamental DataMore

P/E ratio26.982
EPS96.36
Dividend yield1.962 %

Latest discussion posts More

  • xd

    It's unusual to see a rise like that on a day of no news and the share going ex div
    26-Oct-2017
    Hardboy
  • Great results

    A great set of financials, as previously guided. Healthy dividend pay out including a special divi, gives an annualised payout of around 3.5%, based on current share price. A ...
    17-Oct-2017
    smilingmickey1
  • Re: Today's rise

    Results are due to be published on 17th October. They should be quite spectacular to those who are not following closely!
    26-Sep-2017
    smilingmickey1

Users' HoldingsMore

Users who hold Bioventix also hold..
LLOYDS GRP.20%
IQE19%
GLAXOSMITHKLINE19%
BURFORD CAP LD17%
XLMEDIA17%

Codes & Symbols

ISINGB00B4QVDF07
SymbolsBVXP, LSE:BVXP, BVXP.L, BVXP:LN, LON:BVXP, XLON:BVXP

Join interactive investor

  • £22.50 fixed quarterly charge includes £22.50 in trading credits
  • £10 per trade or £6 for frequent traders
  • No % platform fees
  • £1 per trade for regular investment or dividend reinvestment

Open an account